Search Medical Condition
Please enter condition
Please choose location

Prahran VIC, Australia Clinical Trials

A listing of Prahran VIC, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (382) clinical trials

A Double-Blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression

Justification for project TRD is clearly a major health issue - depression is common, results in marked morbidity and mortality and a large percentage of patients do not respond to, or cannot tolerate standard treatment. The development of new treatments for this condition is undoubtedly required. International efforts are underway ...

Phase N/A

0.0 miles

Learn More »

rTMS in the Treatment of Bipolar Depression

Bipolar affective disorder is a serious mental illness with significant mortality and morbidity [1]. Some estimates of prevalence in Western populations are as high as 6.4% [2]. The depressive aspect of bipolar disorder is often overlooked, possibly due to its less dramatic nature, despite its significant impact on the lives ...

Phase

0.0 miles

Learn More »

A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression

TREATMENT OF MAJOR DEPRESSION USING TRANSCRANIAL DIRECT CURRENT STIMULATION Rationale: Depression and tDCS Major depression is a disorder with major clinical and economic significance locally and internationally. It is a disorder of high prevalence and results in substantial disease burden and health-care costs. Critically, a significant percentage of patients, usually ...

Phase N/A

0.0 miles

Learn More »

TMS in the Treatment of the Sequelae of Closed Brain Injury

It is plausible to propose that the same treatment paradigm may result in an improvement in mood and cognition with the possibility that these changes will be self reinforcing resulting in enhanced quality of life and reduced service demands. The proposal for the use of rTMS in the treatment of ...

Phase

0.0 miles

Learn More »

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

This is a first in human phase 1 multicenter open label study to evaluate the safety and tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the dose-expansion. Study medication ...

Phase

0.0 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. NOTE: Global recruitment is complete but enrollment is ongoing for the China sub-study. The Completion Date for the Primary Outcome Measure is expected in October 2018.

Phase

0.0 miles

Learn More »

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.

Phase

0.0 miles

Learn More »

Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)

Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease ...

Phase

0.0 miles

Learn More »

CARILLON Mitral Contour System for Reducing Functional Mitral Regurgitation

The objective of this prospective, multi-center, randomized, double-blind trial is to assess the safety and efficacy of the CARILLON Mitral Contour System in treating functional mitral regurgitation (FMR) associated with heart failure, compared to a randomized Control group which is medically managed according to heart failure guidelines.

Phase N/A

0.0 miles

Learn More »

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Consenting participants will be screened and within 14 days randomly allocated to receive either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the week 12 visit, patients ...

Phase

0.0 miles

Learn More »